Loading clinical trials...
Loading clinical trials...
Phase I Study of C6 Ceramide NanoLiposome (CNL) in Patients With Relapsed/Refractory Acute Myeloid Leukemia (RR-AML)
Conditions
Interventions
Ceramide NanoLiposome (Ceraxa)
Locations
1
United States
University of Virginia Cancer Center
Charlottesville, Virginia, United States
Start Date
October 1, 2025
Primary Completion Date
September 30, 2026
Completion Date
November 30, 2026
Last Updated
March 31, 2026
NCT06459024
NCT05190471
NCT06532084
NCT06125652
NCT05506332
NCT04898894
Lead Sponsor
Keystone Nano, Inc
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions